ClinicalTrials.gg
CompletedNCT02053298Updated Jul 16, 2024

Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients

A Phase 4 interventional study of Timolol & Dorzolamide in Open Angle Glaucoma, sponsored by Universitaire Ziekenhuizen KU Leuven. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Phase 4, Interventional, and Basic science

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Glaucoma is an optic neuropathy in which the main risk factor is intraocular pressure (IOP). The search for other variables involved in glaucoma pathogenesis and progression has identified both systemic and ocular signs of vascular dysfunction in glaucoma patients, such as migraine, peripheral vasospasm, systemic hypotension and cerebral microvascular ischemia. Ocular blood flow studies using Color Doppler Imaging (CDI) technology has demonstrated blood velocities and increased vascular resistance (RI) to exist in such patients when compared to healthy controls. However, a CDI examination provides far more additional information, such as arterial pulsatility (PI) and mean blood velocities (MFV). While these have been used for decades now to study cerebral arteries vasoreactivity, little is known about how these variables are changed in glaucoma patients. We have recently demonstrated that these variables can be used to identify a change in the normal vascular activity when there is increased resistance. In glaucoma patients, a cutpoint in RI of the retrobulbar arteries could be determined beyond which PI increased significantly. This sharp increase in the PI has been used as an indirect signal that the vessel's ability to buffer a decreased perfusion pressure has been surpassed. The normal response to a decreased perfusion in a vascular territory with autoregulation is an increase in dilation in the downstream microcirculation, increasing cross section area in an attempt to keep a steady MFV. As PI is calculated using the vessel's MFV [PI = (PSV-EDV)/MFV], it is highly sensitive to changes in this variable. As such, the cutpoints we have identified in glaucoma patients are therefore an indirect assessment of the vessel's autoregulation limit.

While our data could provide the rational as to why these RI values are associated with progression, the clinical question arises as to whether these cutpoints can be modulated by topical glaucoma therapy. As some medications such as carbonic anhydrase inhibitors have been found to have a positive effect in disease progression in what appears to be a non-IOP related effect, we considered the hypothesis that these drugs could have a positive impact on the ocular's microcirculation vasoactive response, potentially enabling to keep a steady MFV into higher values of vascular resistance.

Read the detailed description

Patients will be recruited from the glaucoma clinic at the department of Ophthalmology in the Leuven University Hospital.

General study setup:

Two cohorts of subjects will be included in the study: primary open-angle glaucoma (POAG) and normal tension glaucoma (NTG) patients. At the screening visit, eligible patients will have their topical therapy replaced by timolol 0.5% bid. At week 4, dorzolamide 2% will be added to the existing treatment in a fixed combination therapy (timolol 0.5%+dorzolamide 2% bid). A final visit at week 8.

At the screening visit (day 0), the patients will undergo a complete ophthalmic investigation with visual acuity, slit lamp biomicroscopy, tonometry, 90 D fundoscopy, automated perimetry, Heidelberg retinal tomography and color Doppler imaging. Blood pressure will also be measured. Topical monotherapy will be replaced by timolol 0.5% bid.

At visit 1 and 2 (timolol - week 4, timolol+dorzolamide week 8, respectively), the patients will undergo ophthalmic investigation with visual acuity, slit lamp biomicroscopy, tonometry, 90 D fundoscopy, blood pressure measurement and color Doppler imaging.

Only one eye will be selected for the study (eye with worst glaucomatous damage). Mann-Whitney test will be used in pairwise comparisons. Restricted cubic sp-lines will be used to verify if there is any evidence for nonlinearity in the relation between the RI and PI. Piecewise linear regression models will be used to determine the optimal cutpoint (i.e. the cutpoint yielding the highest likelihood) in all three visits (baseline, timolol and timolol/dorzolamide). Sensitivity analyses will be performed to verify if the result is not due to an (influential) subject with a high RI value. All data will be expressed in mean ± standard deviation. A two sided p-value \<0.05 is considered significant.

Sample size calculations were made to address the primary outcome (i.e., a change in the RI cutpoints between baseline and last study visit) in the overall glaucoma population (POAG+NTG patients). Based on our previous results10, setting an α error to 5%, power at 80% and the allowable difference at 10% would require the recruitment of 40 patients. Further post hoc analysis will be made to identify differences between the two study cohorts.

02

Conditions studied

  • Open Angle Glaucoma

Keywords

  • Glaucoma
03

In context

Glaucoma, Open-Angle

943 studies on the registry are indexed under Glaucoma, Open-Angle; 118 are open to participants now.

This study's enrollment of 30 is below the median of 80 across 710 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 958 studies on the registry; 263 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • individuals over 18 years old
  • willing to sign an informed consent and able to comply with the requirements of the study
  • having no other ocular diseases besides glaucoma associated with hemodynamic disturbances
  • being either under no topical therapy (naïve patients) or under IOP-lowering monotherapy

Exclusion criteria

Exclusion Criteria:

  • history of ocular trauma
  • intraocular surgery (except for cataract surgery)
  • eye disease associated with hemodynamic disturbances (except glaucoma)
  • systemic diseases with ocular involvement like diabetes
  • contra-indications to the use of topical beta-blockers or carbonic anhydrase inhibitors
05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Timolol & Dorzolamide

    Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month

    Drug: Timolol & Dorzolamide

Interventions

  • DrugTimolol & Dorzolamide

    Drug pages: Timolol · Dorzolamide

    Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month

    Also known as: Cosopt UD

06

What researchers measure

Primary outcomes

  1. Retrobulbar vascular resistance cutpoint change

    The retrobulbar vascular resistance point at which the pulsatility changes will be measured before (baseline), under topical timolol 0.5% and under topical timolol 0.5+dorzolamide 2%

    Time frame: 2 months

07

Study locations

1 site
  • University Hospitals Leuven
    Leuven, Flemish Brabant 3000 Leuven, Belgium
08

References and documents

Publications

  • Abegao Pinto L, Vandewalle E, Stalmans I. Disturbed correlation between arterial resistance and pulsatility in glaucoma patients. Acta Ophthalmol. 2012 May;90(3):e214-20. doi: 10.1111/j.1755-3768.2011.02335.x. Epub 2012 Jan 23. PubMed 22268445 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02053298
Responsible party
Sponsor
First posted
Feb 3, 2014
Start date
Jan 2014
Primary completion
Dec 2015
Completion
Dec 2015
Last update
Jul 16, 2024

Study contacts

Ingeborg Stalmans, MD, PhD
principal investigator · UZ Leuven

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Timolol · Dorzolamide

Start the discussion